SG117434A1 - Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease - Google Patents

Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease

Info

Publication number
SG117434A1
SG117434A1 SG200300701A SG200300701A SG117434A1 SG 117434 A1 SG117434 A1 SG 117434A1 SG 200300701 A SG200300701 A SG 200300701A SG 200300701 A SG200300701 A SG 200300701A SG 117434 A1 SG117434 A1 SG 117434A1
Authority
SG
Singapore
Prior art keywords
alpha
inhibitors
integrin receptor
tgf
kidney disease
Prior art date
Application number
SG200300701A
Other languages
English (en)
Inventor
Cosgrove Dominic
Original Assignee
Boys Town Nat Res Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boys Town Nat Res Hospital filed Critical Boys Town Nat Res Hospital
Publication of SG117434A1 publication Critical patent/SG117434A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00—Materials not provided for elsewhere
    • C09K3/18—Materials not provided for elsewhere for application to surfaces to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Combustion & Propulsion (AREA)
  • Materials Engineering (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG200300701A 1998-05-22 1999-05-19 Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease SG117434A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8658798P 1998-05-22 1998-05-22
US8876698A 1998-06-02 1998-06-02
US15048598A 1998-09-09 1998-09-09

Publications (1)

Publication Number Publication Date
SG117434A1 true SG117434A1 (en) 2005-12-29

Family

ID=56289911

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200300701A SG117434A1 (en) 1998-05-22 1999-05-19 Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease

Country Status (21)

Country Link
EP (1) EP1079843B1 (pt)
JP (1) JP2002516287A (pt)
CN (1) CN1187084C (pt)
AT (1) ATE359804T1 (pt)
BR (1) BR9911067A (pt)
CA (1) CA2329757C (pt)
CZ (1) CZ296262B6 (pt)
DE (1) DE69935853T2 (pt)
DK (1) DK1079843T3 (pt)
EA (1) EA004145B1 (pt)
EE (1) EE04581B1 (pt)
ES (1) ES2285841T3 (pt)
HU (1) HUP0202048A3 (pt)
NO (1) NO20005883L (pt)
NZ (1) NZ508317A (pt)
PL (1) PL345946A1 (pt)
PT (1) PT1079843E (pt)
SG (1) SG117434A1 (pt)
SI (1) SI1079843T1 (pt)
TR (1) TR200003432T2 (pt)
WO (1) WO1999061040A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2529706T3 (es) 1999-06-01 2015-02-24 Biogen Idec Ma Inc. Un anticuerpo monoclonal bloqueante contra el dominio alfa1-I de VLA-1, y su uso para el tratamiento de trastornos inflamatorios
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
CA2384948C (en) * 1999-09-14 2013-07-16 Biogen, Inc. Therapies for chronic renal failure using one or more integrin antagonists
IL151369A0 (en) * 2000-03-09 2003-04-10 Genzyme Corp USE OF TGF-beta ANTAGONISTS FOR PREPARATION OF A PHARMACEUTICAL COMPOSITION
PL367324A1 (en) 2001-04-13 2005-02-21 Biogen, Inc. Antibodies to vla-1
EP1562632B1 (en) * 2002-11-01 2012-12-05 Boys Town National Research Hospital Inducible ligand for alpha1 beta1 integrin and uses
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
CN105381459A (zh) 2006-05-25 2016-03-09 比奥根Ma公司 治疗中风的方法
GB0911888D0 (en) * 2009-07-08 2009-08-19 Oxford Biodynamics Ltd Method of treating age related disorders
US10160808B2 (en) 2012-02-16 2018-12-25 Santarus, Inc. Anti-VLA1 (CD49A) antibody pharmaceutical compositions
KR102118429B1 (ko) 2012-04-25 2020-06-03 사노피 마이크로rna 화합물 및 mir-21 활성 조절 방법
UA116639C2 (uk) * 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
CN104450726A (zh) * 2013-09-17 2015-03-25 深圳华大基因科技有限公司 Col4a5基因突变体及其应用
CN104212806B (zh) * 2014-07-21 2017-05-17 深圳华大基因股份有限公司 Alport综合征新的突变致病基因及其编码蛋白和应用
US20230374141A1 (en) * 2020-10-05 2023-11-23 Father Flanagan's Boys' Home Doing Business As Boys Town National Research Hospital Combination therapy for alport renal disease
CN112575074B (zh) * 2020-10-09 2022-12-27 中山大学 Nestin基因及蛋白在治疗器官纤维化中的应用
WO2023085396A1 (ja) * 2021-11-12 2023-05-19 Ｕｂｅ株式会社 アルポート症候群を治療または予防するための医薬組成物
CN114698592B (zh) * 2022-04-29 2022-11-04 中国医学科学院北京协和医院 一种干燥综合征肾损害小鼠模型的构建方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011718A1 (en) * 1995-09-27 1997-04-03 The Victoria University Of Manchester Inhibitors of integrin receptors and their therapeutical uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011718A1 (en) * 1995-09-27 1997-04-03 The Victoria University Of Manchester Inhibitors of integrin receptors and their therapeutical uses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CELL ADHESION AND COMMUNICATION 1995. VOL 3, NO. 3, PAGES 187-200 *
DEV. BIOL., 1996. VOL. 175, NO. 2, PAGES 301-313 *
GENES AND DEVELOPMENT 1996. VOL. 10, NO. 23, PAGES 2981-2992 *

Also Published As

Publication number Publication date
EA004145B1 (ru) 2004-02-26
CN1310625A (zh) 2001-08-29
BR9911067A (pt) 2001-02-06
EP1079843A2 (en) 2001-03-07
CZ296262B6 (cs) 2006-02-15
WO1999061040A3 (en) 2000-01-27
CA2329757A1 (en) 1999-12-02
JP2002516287A (ja) 2002-06-04
NO20005883D0 (no) 2000-11-21
TR200003432T2 (tr) 2001-03-21
CN1187084C (zh) 2005-02-02
DE69935853T2 (de) 2008-01-10
CA2329757C (en) 2013-11-19
WO1999061040A2 (en) 1999-12-02
NZ508317A (en) 2004-01-30
EE04581B1 (et) 2006-02-15
PT1079843E (pt) 2007-06-26
EP1079843B1 (en) 2007-04-18
PL345946A1 (en) 2002-01-14
ATE359804T1 (de) 2007-05-15
ES2285841T3 (es) 2007-11-16
EA200001092A1 (ru) 2001-06-25
DE69935853D1 (de) 2007-05-31
SI1079843T1 (sl) 2007-10-31
EE200000685A (et) 2002-04-15
NO20005883L (no) 2001-01-17
HUP0202048A3 (en) 2006-11-28
CZ20004358A3 (cs) 2002-01-16
WO1999061040A9 (en) 2001-02-01
HUP0202048A2 (en) 2002-10-28
DK1079843T3 (da) 2007-07-30

Similar Documents

Publication Publication Date Title
SG117434A1 (en) Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
IL143901A0 (en) Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
HK1051005A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
GB9818916D0 (en) Use
HUP0301577A3 (en) Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors, pharmaceutical compositions containing them and their use
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
UA86345C2 (ru) Применение остеопротегерина для лечения и/или предотвращения фиброза
NO992282D0 (no) Benzonaftyridiner som bronkialterapentika
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
ES2185660T3 (es) Nuevo uso de dexmedetomidina.
HUP0104688A2 (hu) Összetételek és eljárások a rákbetegség és a rákbetegséggel kapcsolódó csontveszteség megelőzéséhez és kezeléséhez
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
GR1003490B (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας παροξετινης
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
TR200200278T2 (tr) Kalsilitik bileşimler
WO2001039792A3 (en) The use of caspase 9 inhibitors to treat ocular neural pathology
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
ZA966577B (en) Pharmaceutical composition.
GB9802542D0 (en) New use
AP1747A (en) Use of 6-chloro-5-(2-ä4-Äimino-(2-methylsulfanylphenyl)-methylÜpiperazine-1-ylü-1,3-dihydro-indol-2-one for the preparation of a medicament for the treatment of disorder or condition in a mammal.
ATE323493T1 (de) Gesteuerte freisetzung von antidepressiva